James L Nicklin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/410330/publications.pdf

Version: 2024-02-01

76326 56724 7,330 107 40 83 citations h-index g-index papers 109 109 109 10485 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. New England Journal of Medicine, 2018, 379, 1895-1904.	27.0	1,274
2	Whole–genome characterization of chemoresistant ovarian cancer. Nature, 2015, 521, 489-494.	27.8	1,206
3	Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. Journal of Clinical Epidemiology, 2016, 69, 79-88.	5.0	306
4	Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial. Lancet Oncology, The, 2010, 11, 772-780.	10.7	296
5	Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 1224.	7.4	271
6	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nature Communications, 2018, 9, 3970.	12.8	192
7	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocrine-Related Cancer, 2013, 20, 251-262.	3.1	169
8	Resection of bulky positive lymph nodes in patients with cervical carcinoma. International Journal of Gynecological Cancer, 1995, 5, 250-256.	2 . 5	163
9	Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX? adjuvant in women with cervical intraepithelial neoplasia. Vaccine, 2004, 23, 172-181.	3.8	160
10	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	12.8	144
11	Safety and Efficacy of Low Anterior en Bloc Resection as Part of Cytoreductive Surgery for Patients with Ovarian Cancer. Gynecologic Oncology, 2001, 83, 115-120.	1.4	108
12	ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	107
13	Incidence, risk factors and estimates of a woman's risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer. Gynecologic Oncology, 2015, 136, 87-93.	1.4	100
14	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	12.8	98
15	Endometrial Papillary Serous Carcinoma: Patterns of Spread and Treatment. Clinical Obstetrics and Gynecology, 1996, 39, 686-695.	1.1	94
16	Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. European Journal of Cancer, 2012, 48, 1147-1153.	2.8	86
17	Serum HE4 as a prognostic marker in endometrial cancer — A population based study. Gynecologic Oncology, 2014, 132, 159-165.	1.4	86
18	Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial. American Journal of Obstetrics and Gynecology, 2020, 222, 249.e1-249.e10.	1.3	78

#	Article	IF	Citations
19	Genital Powder Use and Risk of Ovarian Cancer: A Pooled Analysis of 8,525 Cases and 9,859 Controls. Cancer Prevention Research, 2013, 6, 811-821.	1.5	77
20	Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with <i>BRCA1</i> and <i>BRCA2</i> Mutations. Clinical Cancer Research, 2013, 19, 3474-3484.	7.0	76
21	Accuracy of frozen section for the operative management of endometrial cancer. British Journal of Obstetrics and Gynaecology, 2001, 108, 798-803.	0.9	74
22	Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma. Cancer, 2001, 92, 903-908.	4.1	72
23	Prognostic Importance of Preoperative CA-125 in International Federation of Gynecology and Obstetrics Stage I Epithelial Ovarian Cancer: An Australian Multicenter Study. Journal of Clinical Oncology, 2005, 23, 5938-5942.	1.6	71
24	High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecologic Oncology, 2013, 128, 327-334.	1.4	68
25	Local Recurrence in High-Risk Node-Negative Stage I Endometrial Carcinoma Treated with Postoperative Vaginal Vault Brachytherapy. Gynecologic Oncology, 2000, 79, 490-494.	1.4	60
26	Peritoneal cytology: impact on disease-free survival in clinical stage I endometrioid adenocarcinoma of the uterus. Cancer Letters, 2001, 164, 105-110.	7.2	59
27	Impact of weight change and weight cycling on risk of different subtypes of endometrial cancer. European Journal of Cancer, 2013, 49, 2717-2726.	2.8	57
28	Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncology, The, 2020, 21, 851-860.	10.7	57
29	Quality of life of women with lower limb swelling or lymphedema 3–5years following endometrial cancer. Gynecologic Oncology, 2014, 133, 314-318.	1.4	56
30	Efficacy of routine follow-up in patients with recurrent uterine cancer. Gynecologic Oncology, 2007, 107, 124-129.	1.4	54
31	A Clinicopathological Study of Adenocarcinoma in Situ of the Cervix. The Influence of Cervical HPV Infection and Other Factors, and the Role of Conservative Surgery. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1991, 31, 179-183.	1.0	53
32	Splenectomy as Part of Cytoreductive Surgery for Ovarian Carcinoma. Gynecologic Oncology, 1995, 58, 244-247.	1.4	52
33	Fertility and Ovarian Function After Conservative Surgery for Germ Cell Tumours of the Ovary. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1999, 39, 243-245.	1.0	51
34	The functional assessment of cancer-vulvar: Reliability and validity. Gynecologic Oncology, 2005, 97, 568-575.	1.4	51
35	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Human Molecular Genetics, 2015, 24, 1478-1492.	2.9	50
36	Metastasis of ovarian cancer is mediated by kallikrein related peptidases. Clinical and Experimental Metastasis, 2014, 31, 135-147.	3.3	47

#	Article	IF	Citations
37	Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis. European Journal of Nutrition, 2013, 52, 705-715.	3.9	46
38	Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. Gynecologic Oncology, 2021, 161, 143-151.	1.4	46
39	Patterns of recurrence and disease-free survival in advanced squamous cell carcinoma of the vulva. Gynecologic Oncology, 2004, 95, 701-705.	1.4	44
40	Endometrial adenocarcinoma - presenting pathology is a poor guide to surgical management. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2000, 40, 191-194.	1.0	43
41	Pre-diagnosis diet and survival after a diagnosis of ovarian cancer. British Journal of Cancer, 2017, 116, 1627-1637.	6.4	42
42	Accuracy of frozen section for the operative management of endometrial cancer. BJOG: an International Journal of Obstetrics and Gynaecology, 2001, 108, 798-803.	2.3	39
43	Prevalence, predictors, and correlates of supportive care needs among women 3–5Âyears after a diagnosis of endometrial cancer. Supportive Care in Cancer, 2015, 23, 1205-1214.	2.2	39
44	Evaluation of a Maternity Cushion (Ozzlo Pillow) for Backache and Insomnia in Late Pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1989, 29, 133-138.	1.0	37
45	Postoperative Vaginal Vault Brachytherapy for Node-Negative Stage II (Occult) Endometrial Carcinoma. Gynecologic Oncology, 2001, 81, 193-195.	1.4	36
46	The utility of serum CAâ€125 in predicting extraâ€uterine disease in apparent earlyâ€stage endometrial cancer. International Journal of Cancer, 2012, 131, 885-890.	5.1	35
47	Early-stage vaginal carcinoma - an analysis of 70 patients. International Journal of Gynecological Cancer, 2004, 14, 304-310.	2.5	33
48	Risk factors to predict the incidence of surgical adverse events following open or laparoscopic surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. European Journal of Cancer, 2012, 48, 2155-2162.	2.8	33
49	Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2007, 47, 504-507.	1.0	31
50	Primary fallopian tube carcinoma: the Queensland experience. International Journal of Gynecological Cancer, 2001, 11, 69-72.	2.5	30
51	Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: Effect on progression-free survival. International Journal of Gynecological Cancer, 2003, 13, 633-639.	2.5	30
52	Validation of the FIGO 2009 Staging System for Carcinoma of the Vulva. International Journal of Gynecological Cancer, 2012, 22, 498-502.	2.5	30
53	Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer – A population-based study. Gynecologic Oncology, 2013, 129, 310-317.	1.4	30
54	Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer. British Journal of Cancer, 2014, 111, 234-240.	6.4	30

#	Article	IF	Citations
55	Primary Bartholin gland carcinoma: a report of seven cases. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2001, 41, 78-81.	1.0	29
56	Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer. International Journal of Gynecological Cancer, 2021, 31, 647-655.	2.5	28
57	Nomograms to predict isolated loco-regional or distant recurrence among women with uterine cancer. Gynecologic Oncology, 2012, 125, 520-525.	1.4	27
58	The Impact of Positive Peritoneal Washings and Serosal and Adnexal Involvement on Survival in Patients with Stage IIIA Uterine Cancer. Gynecologic Oncology, 2002, 86, 269-273.	1.4	26
59	Improving identification of lynch syndrome patients: A comparison of research data with clinical records. International Journal of Cancer, 2013, 132, 2876-2883.	5.1	26
60	Microinvasive Adenocarcinoma of the Cervix. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1999, 39, 411-413.	1.0	24
61	Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Scientific Reports, 2014, 4, 4669.	3.3	24
62	The Significance of Psammoma Bodies on Cervical Cytology Smears. Gynecologic Oncology, 2001, 83, 6-9.	1.4	23
63	Evaluation of Tumor-Free Distance and Depth of Myometrial Invasion as Prognostic Factors for Lymph Node Metastases in Endometrial Cancer. International Journal of Gynecological Cancer, 2010, 20, 1217-1221.	2.5	23
64	Predictors of sexual well-being after endometrial cancer: results of a national self-report survey. Supportive Care in Cancer, 2014, 22, 2715-2723.	2.2	22
65	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings, 2018, 93, 307-320.	3.0	22
66	High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival. PLoS ONE, 2013, 8, e54356.	2.5	22
67	An anatomical study of inguinal lymph node topography and clinical implications for the surgical management of vulval cancer. International Journal of Gynecological Cancer, 1995, 5, 128-133.	2.5	20
68	Total laparoscopic hysterectomy: The Brisbane learning curve. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2007, 47, 65-69.	1.0	20
69	Analysis of Prognostic Variables, Development of Predictive Models, and Stratification of Risk Groups in Surgically Treated FIGO Early-Stage (IA–IIA) Carcinoma Cervix. International Journal of Gynecological Cancer, 2012, 22, 115-122.	2.5	19
70	Neoadjuvant Chemotherapy Followed by Radical Vaginal Trachelectomy and Adjuvant Chemotherapy for Clear Cell Cancer of the Cervix: A Feasible Approach and Review. International Journal of Gynecological Cancer, 2011, 21, 137-140.	2.5	18
71	The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2017, 57, 651-658.	1.0	16
72	Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer. Genome Medicine, 2022, 14, 3.	8.2	16

#	Article	IF	CITATIONS
73	Malignant Transformation Within Ovarian Dermoid Cysts. International Journal of Gynecological Cancer, 2010, 20, 75-81.	2.5	15
74	Occasional Review: Systemic Lupus Erythematosus and Pregnancy at the Royal Women's Hospital, Brisbane 1979–1989. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1991, 31, 128-133.	1.0	13
75	Stage 3B Adenocarcinoma of the Endometrium: A Clinicopathologic Study. Gynecologic Oncology, 2000, 78, 203-207.	1.4	13
76	RANDOMIZED TRIAL OF SKIN CLOSURE AFTER LAPAROTOMY FOR GYNAECOLOGICAL SURGERY. ANZ Journal of Surgery, 2007, 77, 460-463.	0.7	13
77	Basal cell carcinoma of the vulva: A report of four cases. Australasian Journal of Dermatology, 2008, 49, 213-215.	0.7	13
78	Consideration for safe and effective gynaecological laparoscopy in the obese patient. Archives of Gynecology and Obstetrics, 2015, 292, 135-141.	1.7	13
79	Quality of life after early enteral feeding versus standard care for proven or suspected advanced epithelial ovarian cancer: Results from a randomised trial. Gynecologic Oncology, 2015, 137, 516-522.	1.4	13
80	Disease-free survival after vaginal vault brachytherapy versus observation for patients with node-negative intermediate-risk endometrial adenocarcinoma. Gynecologic Oncology, 2008, 110, 280-285.	1.4	12
81	Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma. Gynecologic Oncology, 2011, 120, 179-184.	1.4	12
82	CHEK2, MGMT, SULT1E1 and SULT1A1 Polymorphisms and Endometrial Cancer Risk. Twin Research and Human Genetics, 2011, 14, 328-332.	0.6	12
83	The future of roboticâ€assisted laparoscopic gynaecologic surgery in Australia – A time and a place for everything. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2017, 57, 493-498.	1.0	12
84	Low Malignant Potential Ovarian Tumours: A Review of 175 Consecutive Cases. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1997, 37, 100-103.	1.0	11
85	A Comparison of Ovarian Cyst Aspirate Cytology and Histology. The Case Against Aspiration of Cystic Pelvic Masses. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1994, 34, 546-549.	1.0	10
86	Evaluation of restaging in clinical stage 1A low malignant potential ovarian tumours. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2002, 42, 381-384.	1.0	10
87	Hospital costs associated with adverse events in gynecological oncology. Gynecologic Oncology, 2011, 121, 70-75.	1.4	9
88	Cervical perivascular epithelioid cell tumour (PEComa) of the uterine cervix: cytological findings in a cervical smear. Cytopathology, 2013, 24, 272-273.	0.7	9
89	Clinicopathological study of ovarian carcinoid tumours. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2016, 56, 508-513.	1.0	9
90	Radical Trachelectomy for early stage cervical cancer: The Queensland experience. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2014, 54, 450-452.	1.0	8

#	Article	IF	Citations
91	Radical Surgery for Endometriosis. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1999, 39, 68-74.	1.0	5
92	Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. Journal of Gynecologic Oncology, 2021, 32, e95.	2.2	5
93	A carcinoid tumor of the broad ligament. Obstetrics and Gynecology, 1998, 92, 708.	2.4	4
94	Thromboembolic Complications in Gynecologic Surgery. Clinical Obstetrics and Gynecology, 2002, 45, 545-552.	1.1	4
95	Genetic Variants in ER Cofactor Genes and Endometrial Cancer Risk. PLoS ONE, 2012, 7, e42445.	2.5	4
96	Cervical cancer in women under 25Âyears of age in Queensland, Australia: To what extent is the diagnosis made by screening cytology?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2017, 57, 469-472.	1.0	4
97	Intracardiac Leiomyomatosis – an Unusual Cause of Syncope in a Middle-Aged Woman. Heart Lung and Circulation, 2017, 26, e22-e25.	0.4	4
98	Feasibility and Outcomes of Ureteroureterostomy and Extravesical Ureteroneocystostomy as Part of Radical Surgery for Infiltrating Gynecologic Disease. International Journal of Gynecological Cancer, 2013, 23, 1139-1145.	2.5	3
99	Patient experiences of conservative treatment for early stage endometrial cancer and endometrial hyperplasia with atypia using levonorgestrel intrauterine device: A qualitative study. Gynecologic Oncology Reports, 2022, 39, 100914.	0.6	3
100	Re: Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage 1. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2008, 48, 447-447.	1.0	1
101	Randomized controlled trial of laparoscopic approach to carcinoma of the endometrium (LACE): Prevalence and risk factors for surgical complications. Gynecologic Oncology, 2011, 120, S10.	1.4	1
102	The use of an overlay autogenous tissue (OAT) patch to control intra-operative haemorrhage of the spleen. Gynecologic Oncology, 2005, 99, 225-227.	1.4	0
103	The utility of preoperative CA-125 in the management of apparent early-stage endometrial cancer. Gynecologic Oncology, 2011, 120, S17.	1.4	0
104	Charlson's index: A validation study to predict surgical adverse events in gynecologic oncology. Gynecologic Oncology, 2011, 120, S121.	1.4	0
105	Re: Radical Trachelectomy for early stage cervical cancer. The Queensland experience. ANZJOG 2014; 54(5):450-452. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2015, 55, 298-299.	1.0	0
106	Author's Right of Reply: Cervical cancer in women under 25 years of age in Queensland, Australia: To what extent is the diagnosis made by screening cytology?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2018, 58, E6-E6.	1.0	0
107	Malignant ovarian germ cell tumours in the postâ€menopausal population. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2019, 59, 285-287.	1.0	0